Diagnosis of Disseminated Intravascular Coagulation by Hemostatic Molecular Markers

Hideo Wada; Esteban Gabazza; Takahiro Nakasaki; Minori Shimura; Kazuyo Hiyoyama; Katsumi Deguchi; Masakatsu Nishikawa; Nobuo Sakuragawa; Hiroshi Shiku

doi:10.1055/s-2000-9797

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2000; Volume 26(Number 01): 017-022
DOI: 10.1055/s-2000-9797

Diagnosis of Disseminated Intravascular Coagulation by Hemostatic Molecular Markers

Hideo Wada¹ , Esteban Gabazza² , Takahiro Nakasaki¹ , Minori Shimura¹ , Kazuyo Hiyoyama¹ , Katsumi Deguchi¹ , Masakatsu Nishikawa¹ , Nobuo Sakuragawa³ , Hiroshi Shiku¹

Supported in part by a Grant-In-Aid for Cancer Research from the Ministry of Education, Science and Culture, Japan.
¹Second Department of Internal Medicine, Mie University School of Medicine, Tsu-City, Japan
²Third Department of Internal Medicine, Mie University School of Medicine, Tsu-City, Japan
³Department of Clinical Pathology, Toyama Medical & Pharmaceutical University, Toyama-City, Japan

Abstract

ABSTRACT

In the present study, the positive rate of thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex (PPIC), soluble fibrin monomer (sFM), and D-dimer for the diagnosis of disseminated intravascular coagulation (DIC) was evaluated. The study comprised 307 patients with DIC, 123 with pre-DIC, and 121 with non-DIC. Plasma levels of TAT, PPIC, sFM, and D-dimer were significantly higher in DIC and pre-DIC patients than in non-DIC patients. In DIC patients, the positive rate of sFM was high and that of D-dimer was low; the positive rate of PPIC was higher in patients with hematopoietic malignancy than in those without this disease. In pre-DIC patients, the positive rate of all markers was low (<0.16), and the positive rate of PPIC was relatively high. In non-DIC patients, the positive rate of all hemostatic markers was low (<0.16), that of sFM being the lowest. Scoring the positive rate of TAT, PPIC, and sFM disclosed the following results: 72% of DIC patients had three or more points, 17.6% of pre-DIC patients had three or more points, and almost all (96.6%) non-DIC patients had two or less points. Scoring the positive rate of TAT, PPIC, and D-dimer disclosed the following results: 52.9% of DIC patients and 27.4% of pre-DIC patients had three or more points and almost all (96.7%) non-DIC patients had 2 or less points. These data suggest that the combination of TAT, PPIC, and sFM is useful for making the diagnosis of DIC.

KEYWORD

DIC - pre-DIC - TAT - PPIC - sFM

Full Text

References

REFERENCES

1 Bick R L. Disseminated intravascular coagulation and related syndromes: A clinical review. Semin Thromb Hemost . 1998; 14 299-338
2 Müller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemost . 1989; 15 58-98
3 Kobayashi N, Maegawa K, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol . 1987; 49 265-275
4 Wada H, Minamikawa K, Wakita Y. Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol . 1994; 43 265-275
5 Ohno H, Kambayashi J, Chang S W, Kosaki G. FOY;[ethyl p(6-guanidino-hexanoxyloxy) benzoate] methanesulfonate as a serine protease inhibitor. II. In vivo effect on coagulofibrinolytic system in comparison with heparin or aprotinin. Thromb Res . 1980; 24 455-452
6 Sakuragawa N, Hasegawa H, Maki M, Nakagawa M, Nakashima M. Clinical evaluation of low-molecular weight heparin (FR-860) on disseminated intravascular coagulation (DIC). A multicentric cooperative double blind trial in comparison with heparin. Thromb Res . 1993; 72 475-500
7 Larcan A, Lambert H, Gerard A. Treatment of Consumption Coagulopathies. Paris: Masson Publishing, 1987: 165-181
8 Wada H, Wakita Y, Nakase T. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost . 1995; 74 848-852
9 Rylatt D B, Blake A S, Cottis L E. An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res . 1983; 31 767-778
10 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost . 1987; 59 101-106
11 Mimuro J, Koike Y, Sumi Y, Aoki N. Monoclonal antibodies to discrete regions in α2-plasmin inhibitor. Blood . 1987; 69 446-452
12 Wada H, Wakita Y, Nakase T. Increased plasma soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol . 1996; 51 255-260
13 Wada H, Tomeoku M, Deguchi A. Anticoagulant activity in cell homogenate of adult T cell leukemia. Thromb Haemost . 1988; 59 197-201
14 Wada H, Sakuragawa N, Shiku H. Hemostatic molecular markers before onset of disseminated intravascular coagulation in leukemic patients. Semin Thromb Hemost . 1998; 24 293-297
15 Wada H, Nakase T, Nakaya R. Elevated plasma tissue factor antigen levels in patients with disseminated intravascular coagulation. Am J Hematol . 1994; 45 232-236
16 Shimura M, Wada H, Wakita Y. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol . 1996; 52 165-170
17 Wada H, Minamikawa K, Wakita Y. Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation. Am J Hematol . 1993; 44 85-88
18 Wada H, Mori Y, Shimura M. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol . 1998; 58 189-194